NCT05186909View on ClinicalTrials.gov

A Study of CM310 in Subjects With Moderate to Severe Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions
Asthma
Interventions
DRUG

CM310

CM310 Recombinant Humanized Monoclonal Antibody Injection

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

China-Japan Friendship Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05186909 - A Study of CM310 in Subjects With Moderate to Severe Asthma | Biotech Hunter | Biotech Hunter